TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03240965

Intervention type: DIAGNOSTIC_TEST
Intervention: FEES (flexible endoscopic evaluation of swallowing)
Description: Endoscopical swallowing study in stroke patients only

Intervention type: OTHER
Intervention: Sensitivity threshold
Description: Determining sensitivity threshold using a pudendal electrode

Intervention type: OTHER
Intervention: Sensitivity threshold
Description: Determining sensitivity threshold using a pudendal electrode

Intervention type: OTHER
Intervention: Sensitivity threshold
Description: Determining sensitivity threshold using a pudendal electrode

Intervention type: DIAGNOSTIC_TEST
Intervention: Taste-/smell-test
Description: Taste-/smell-test

Intervention type: DIAGNOSTIC_TEST
Intervention: Taste-/smell-test
Description: Taste-/smell-test
Study: NCT03240965

Intervention type: DIAGNOSTIC_TEST
Intervention: Taste-/smell-test
Description: Taste-/smell-test
Study: NCT00444600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide + laser
Description: 4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser
Description: 0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection + laser
Description: Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab + deferred laser
Description: 0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
Study: NCT01674647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Description: VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
Study: NCT00117403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E, Vitamin C, and Alpha-lipoic Acid
Description: vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q
Description: 400 mg, compounded as a wafer, two wafers three times per day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: one placebo capsule three times per day with meals
Study: NCT03996278

Intervention type: OTHER
Intervention: Grafalon
Description: None interventional study but there are two groups

Intervention type: OTHER
Intervention: Grafalon
Description: None interventional study but there are two groups
Study: NCT03740009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogen
Description: 20 mg bazedoxifene/0.45mg conjugated estrogens tablets
Study: NCT01394510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
Study: NCT00819325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 30mg p.o. once a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral hypoglycemic agents
Description: sulfonylurea or metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hypoglycemic agents
Description: sulfonylurea or metformin
Study: NCT03474822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage infection of P.vivax
Description: The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
Study: NCT02539108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2015 2016 formulation)
Study: NCT01981837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-TTRSC (revusiran) for subcutaneous administration
Study: NCT02976116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
Study: NCT04534036

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachets will contain potato or tapioca maltodextrin.
Study: NCT03497429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study: NCT03121833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Recombinant Human Endostatin Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500ml 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIM regimen / GT regimen
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIM regimen / GT regimen
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)
Study: NCT03799926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
Study: NCT00762372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: volatile liquid for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane/nitrous oxide
Description: volatile liquid for inhalation with gas for inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane/nitrous oxide
Description: volatile liquid for inhalation and gas for inhalation
Study: NCT03364335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 1.0mg
Description: Leu 1100 mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 1.0mg
Description: Leu 1100 mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 1.0mg
Description: Leu 1100 mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 1.0mg
Description: Leu 1100 mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 4.0mg
Description: Leu 1100 mg + 4mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 4.0mg
Description: Leu 1100 mg + 4mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 1.0mg
Description: Leu 1100 mg + Met 500mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 1.0mg
Description: Leu 1100 mg + Met 500mg + 1mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 4.0mg
Description: Leu 1100 mg + Met 500mg + 4mg Sil BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 4.0mg
Description: Leu 1100 mg + Met 500mg + 4mg Sil BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04406935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment with the study device (NuEra)
Description: Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment with the study device (NuEra)
Description: Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment with the study device (NuEra)
Description: Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz
Study: NCT01431144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue autograft
Description: A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue allograft
Description: An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
Study: NCT03726619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CHEC-uP
Description: One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHEC-uP
Description: One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
Study: NCT01493310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Given by intravenous infusion (IV)~Dose of 80 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Given by intravenous infusion (IV)~Dose of 80 mg/m2
Study: NCT04275245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized MAb against CD147
Study: NCT00360698

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glargine
Description: One daily injection at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glargine
Description: One daily injection at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Glimepiride
Description: At same dosage as during the run-in period
Study: NCT01967745

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.

Intervention type: PROCEDURE
Intervention: open appendectomy
Description: The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
Study: NCT00360698

Intervention type: DRUG
Group type: OTHER
Intervention: Glimepiride
Description: At same dosage as during the run-in period

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glulisine
Description: One bolus given before the main meal

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: At same dosage as during the run-in period

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: At same dosage as during the run-in period
Study: NCT01043458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose \& ABT-126 High Dose
Study: NCT00117403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: one placebo capsule three times per day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo wafers
Description: two placebo wafers three times per day with meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wafers
Description: two placebo wafers three times per day with meals
Study: NCT03407118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC.
Study: NCT00869024

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Description: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Description: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
Study: NCT04072276

Intervention type: BIOLOGICAL
Intervention: EV71 vaccine
Description: EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study

Intervention type: BIOLOGICAL
Intervention: EV71 vaccine
Description: EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
Study: NCT03465748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoK
Description: orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
Study: NCT01043458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose \& ABT-126 High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-126
Description: Matching Placebo for Arms 1 \& 2
Study: NCT00883155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl 100 mg Tablets (Invamed Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin 100 mg Tablets (Glaxo Wellcome)
Study: NCT04136145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab for IV
Description: Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab for SC
Description: Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
Study: NCT01198587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
Study: NCT03200002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
Study: NCT02259816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study: NCT02834455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced CT
Description: 50% of patients with unilateral pleural effusion will have performed a CE-CT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET-CT
Description: 50% of patients with unilateral pleural effusion will have performed a PET-CT
Study: NCT00986882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT04167943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual cured resin modified tricalcium silicate cement
Description: A resin based, dual cured tricalcium silicate based cement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual cured resin modified tricalcium silicate cement
Description: A resin based, dual cured tricalcium silicate based cement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual cured resin modified tricalcium silicate cement
Description: A resin based, dual cured tricalcium silicate based cement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual cured resin modified tricalcium silicate cement
Description: A resin based, dual cured tricalcium silicate based cement
Study: NCT01252680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive+Healive
Description: Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive+Havrix
Description: Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix+Havrix
Description: Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix+Healive
Description: Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
Study: NCT02569853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo